The serological testing market is expected to grow at a 6.11% CAGR, achieving USD 8.727 billion in 2031 from USD 6.114 billion in 2025.
Highlights:
- 1Rising establishment of blood banks worldwide is significantly driving market growth due to increasing demand for safe blood screening and transfusion testing.
- 2Growing hospital infrastructure and increasing prevalence of infectious diseases are accelerating the adoption of serological testing for accurate diagnosis and patient monitoring.
- 3Public health initiatives and government investments in disease surveillance, vaccination programs, and healthcare infrastructure are supporting market expansion globally.
- 4Serological testing plays a critical role in detecting infectious diseases such as HIV, hepatitis, rotavirus, and other transfusion-transmissible infections.
Serological testing is a laboratory test that analyses a blood sample to detect the presence of antibodies or other substances, providing valuable information about a person's immune response. The serological testing industry caters to the needs of medical institutions such as hospitals, clinics, diagnostic laboratories, and blood banks that rely on such testing for accurate diagnoses, monitoring patient health, and ensuring the safety of blood transfusions. The growing establishment of new hospitals and blood banks play vital roles as prominent drivers in augmenting the serological testing market size.
Serological Testing Market Drivers:
Booming blood bank establishment bolsters the serological testing market growth.
Serological testing is done in blood banks to ensure the safety of donated blood and blood products. These tests help identify the presence of specific antibodies or antigens in the blood samples. Blood banks are responsible for conducting serological tests to screen donated blood for infectious diseases, such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible infections.
The rise in hospitals' strength drives the serological market expansion.
Serological testing is used in hospitals as it provides crucial information about a patient's immune response, aiding in accurate diagnoses and monitoring of various diseases. Hospitals rely on serological tests to identify antibodies, detect infectious agents, assess vaccination status, and determine immune system function. The increasing demand for serological testing in hospitals is driven by the growing prevalence of infectious diseases and as hospitals continue to expand, demand for serological testing rises. According to the American Hospital Association, the total number of hospitals in the United States experienced an increase in 2023, reaching 6,129, compared to the previous count of 6,090 hospitals in 2021.
An increase in public health initiatives drives the serological testing market growth.
Serological testing due to its ability to identify the presence of antibodies in blood samples is experiencing a boost in public health checkups. Governments worldwide are investing in testing infrastructure, research, and development, and screening programs to control disease outbreaks, monitor population immunity, and ensure blood safety which is accelerating the demand for serological testing. According to the World Health Organization, in 2020, the United States extended a significant contribution of $84 million to WHO and UNICEF which played a vital role in bolstering global surveillance, sustaining the laboratory network, procuring vaccines, providing technical assistance to countries, and fostering community mobilization efforts.
Serological Testing Market Geographical Outlook:
Asia-Pacific is estimated to dominate the market.
Asia-Pacific will hold a significant share of the serological testing market as the region is experiencing rapid expansion in its healthcare sector, infrastructure development, medical facilities, and technological advancements. This growth is fuelling the demand for serological testing as a critical diagnostic tool. Moreover, government investments in healthcare policies and public health campaigns further support the growth of the serological testing industry in Asia-Pacific. For instance, in the Union Budget 2023-24, the Ministry of Health and Family Welfare received an allocation of Rs. 89,155 crore representing a growth of 3.43% from the previous year's allocation of Rs. 86,200.65 crore in 2021-22.
Serological Testing Market Restraints:
High cost restrains the serological testing market growth.
The cost of serological tests can be a significant hindrance to their adoption, particularly in regions with limited healthcare budgets or where reimbursement systems do not adequately cover these tests. This challenge is particularly pronounced when advanced technologies or multiplex assays are used, as they often involve higher expenses. The high cost of testing acts as a barrier, limiting access to serological testing and preventing its widespread utilization, especially in resource-constrained settings where budgetary constraints play a crucial role in healthcare decision-making.
List of Top Serological Testing Companies:
Randox Laboratories Ltd
Abbott
Bio-Rad Laboratories Inc.
BD
Thermo Fisher Scientific Inc.
Serological Testing Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 6.114 billion |
| Total Market Size in 2031 | USD 8.727 billion |
| Forecast Unit | USD Billion |
| Growth Rate | 6.11% |
| Study Period | 2020 to 2031 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2031 |
| Segmentation | Test Type, Application, End-user, Geography |
| Companies |
|
Market Segmentation
By Test Type
By Application
By End-user
By Geography
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. SEROLOGICAL TESTING MARKET BY TEST TYPE
5.1. Introduction
5.2. Primary Serological Tests
5.2.1. Enzyme Linked Immunosorbent Assay (ELISA)
5.2.2. Immunofluorescent Antibody Technique (IFAT)
5.2.3. Radio Immunoassay (RIA)
5.3. Secondary Serological Tests
5.3.1. Agglutination Tests
5.3.2. Complement Fixation Tests (CFT)
5.3.3. Precipitation Tests
5.4. Serum Neutralization Tests (SNT)
5.4.1. Toxin-antitoxin Tests
5.4.2. Tertiary Binding Tests
6. SEROLOGICAL TESTING MARKET BY APPLICATION
6.1. Introduction
6.2. Rotavirus
6.3. Hepatitis
6.4. HIV
6.5. Endotoxins
6.6. Therapeutic Drug Monitoring
6.7. Other Infectious Diseases
7. SEROLOGICAL TESTING MARKET BY END-USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Diagnostic Laboratories
7.4. Blood Banks
7.5. Others
8. SEROLOGICAL TESTING MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Serological Research Institute (SERI) (U.K.)
10.2. Chembio Diagnostics, Inc (U.S.)
10.3. Cellex (U.S.)
10.4. Randox Laboratories Ltd (U.K.)
10.5. Abbott (U.S.)
10.6. Bio-Rad Laboratories Inc. (U.S.)
10.7. BD (U.S.)
10.8. Thermo Fisher Scientific Inc. (U.S.)
10.9. Ortho Clinical Diagnostics (U.S.)
10.10. Quest Diagnostics Incorporated (U.S.)
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES
Navigate
Trusted by the world's leading organizations
